Medicare Enrolled

Dr. Christopher Stokoe, MD

Medical Oncology · Plano, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
3705 W 15TH ST, Plano, TX 75075
9728673577
In practice since 2006 (19 years)
NPI: 1801839758 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Stokoe from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Stokoe? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Stokoe

Dr. Christopher Stokoe is a medical oncology in Plano, TX, with 19 years in practice. Based on federal Medicare data, Dr. Stokoe performed 56,944 Medicare services across 3,957 unique beneficiaries.

Between the years covered by Open Payments, Dr. Stokoe received a total of $77,266 from 45 pharmaceutical and/or device companies across 203 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Stokoe is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 19% volume in TX$ $77,266 industry payments

Medicare Practice Summary

Medicare Utilization ↗
56,944
Medicare services
Top 19% in TX for medical oncology
3,957
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,997 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron sucrose injection (Venofer)19,000$0$2
Darbepoetin injection (Aranesp) for anemia11,875$2$20
Contrast dye for imaging (iodine-based)6,840$0$3
Pembrolizumab injection (Keytruda)4,400$43$137
Paclitaxel chemotherapy injection2,774$0$8
Denosumab injection (Prolia/Xgeva)1,740$18$66
Immune globulin infusion (Octagam)1,330$34$234
Dexamethasone injection (steroid)1,044$0$1
Blood draw (venipuncture)1,040$8$20
Complete blood count (CBC) with differential949$8$36
Comprehensive metabolic blood panel941$10$64
Injection, granisetron hydrochloride, 100 mcg650$0$24
Office visit, established patient (30-39 min)497$90$368
Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3383$20$128
Anti-nausea injection (Aloxi/palonosetron)350$1$114
Injection of additional new drug or substance into vein301$12$108
Office visit, established patient (20-29 min)227$55$250
Administration of chemotherapy into vein, 1 hour or less184$98$707
Ferritin level test (iron stores)169$13$60
Iron level test166$6$27
Iron binding capacity test166$9$35
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries149$89$657
Nuclear medicine study from skull base to mid-thigh with ct scan143$1,109$4,802
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less141$47$313
Injection, carboplatin, 50 mg135$2$300
Drug injection, under skin or into muscle98$10$96
Ct scan of chest with contrast76$42$821
Lactate dehydrogenase (enzyme) level74$6$31
Injection, diphenhydramine hcl, up to 50 mg69$1$7
Injection, zoledronic acid, 1 mg65$7$431
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less64$22$157
CT scan of abdomen and pelvis with contrast63$165$1,067
Carcinoembryonic antigen (cea) protein level63$19$99
Microscopic examination for white blood cells with manual cell count60$4$22
Complete blood count (CBC), automated60$6$34
Administration of additional new drug or substance into vein, 1 hour or less59$49$344
Unclassified drugs59$1$8
Infusion, normal saline solution , 1000 cc55$2$19
Administration of chemotherapy into vein, each additional hour53$21$161
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle52$54$211
Office visit, established patient, complex (40-54 min)49$123$496
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour43$16$100
New patient office visit (45-59 min)37$124$565
Infusion into a vein for hydration, each additional hour31$10$75
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle31$26$145
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion28$15$94
Reticulated (young) platelet measurement24$35$143
Drawing of blood for a medical problem22$70$264
Infusion into a vein for hydration, 31-60 minutes20$23$256
CT scan of chest, without contrast19$29$686
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg19$340$1,722
Red blood count automated, with additional calculations16$5$26
Ct scan of abdomen and pelvis without contrast15$65$560
Blood creatinine level15$5$31
Chest X-ray, 2 views11$8$61
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.0% high complexity
87.8% medium
9.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$77,266
Total received (2018-2024)
Avg $11,038/year across 7 years
Top 18% in TX for medical oncology
45
Companies
203
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$44,077 (57.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$30,888 (40.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,300 (3.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$663
2023
$2,918
2022
$11,026
2021
$8,874
2020
$17,318
2019
$9,144
2018
$27,324

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Puma Biotechnology, Inc.
$54,220
PUMA BIOTECHNOLOGY, INC.
$16,601
Seagen Inc.
$2,150
AstraZeneca Pharmaceuticals LP
$2,122
Merck Sharp & Dohme LLC
$191
GlaxoSmithKline, LLC.
$184
Novartis Pharmaceuticals Corporation
$174
Daiichi Sankyo Inc.
$145
Janssen Biotech, Inc.
$129
Incyte Corporation
$124
Karyopharm Therapeutics Inc.
$83
Regeneron Healthcare Solutions, Inc.
$67
Amgen Inc.
$65
GENZYME CORPORATION
$63
BeiGene USA, Inc.
$60
Pharmacyclics LLC, An AbbVie Company
$59
ABBVIE INC.
$57
E.R. Squibb & Sons, L.L.C.
$55
Ipsen Biopharmaceuticals, Inc
$54
PFIZER INC.
$50
Eisai Inc.
$49
Lilly USA, LLC
$46
SOBI, INC
$45
Jazz Pharmaceuticals Inc.
$45
EMD Serono, Inc.
$37
Kite Pharma, Inc.
$31
Stemline Therapeutics Inc.
$29
AbbVie Inc.
$25
Celgene Corporation
$24
Sumitomo Pharma America, Inc.
$23
Adaptive Biotechnologies Corporation
$22
GE HealthCare
$21
Apellis Pharmaceuticals, Inc.
$21
Rigel Pharmaceuticals, Inc.
$20
Iovance Biotherapeutics, Inc.
$20
Blueprint Medicines Corporation
$20
Taiho Oncology, Inc.
$18
Kyowa Kirin, Inc.
$17
Takeda Pharmaceuticals U.S.A., Inc.
$17
Bayer Healthcare Pharmaceuticals Inc.
$16
ADC Therapeutics America, Inc.
$16
Exelixis Inc.
$16
G1 Therapeutics, Inc.
$14
Acrotech Biopharma LLC
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 94.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Amtagvi · BAVENCIO · BELEODAQ · BLENREP · BRUKINSA · CABLIVI · COSELA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ENHERTU · EPKINLY · Empaveli · Enhertu · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · KEYTRUDA · KISQALI · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NERLYNX · Nerlynx · Nplate · OJJAARA · OPDIVO · ORGOVYX · Onivyde · Orserdu · PADCEV · Poteligeo · REBLOZYL · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · Stivarga · TECVAYLI · TEPMETKO · TEVIMBRA · TUKYSA · VENCLEXTA · VERZENIO · XPOVIO · XTANDI · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (57%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $136 per 100 Medicare services performed
Looking for a medical oncology in Plano?
Compare medical oncologys in the Plano area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
75
Per 100K population
6.7
County median income
$117,588
Nearest hospital
MEDICAL CITY PLANO
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Stokoe is a mixed practice specialist, with above-average Medicare volume (top 19% in TX), and high industry engagement (speaking/promotional, top 18%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Stokoe experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Stokoe performed 19,000 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Stokoe receive payments from pharmaceutical companies?
Yes. Dr. Stokoe received a total of $77,266 from 45 companies across 203 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Stokoe's costs compare to other medical oncologys in Plano?
Dr. Stokoe's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Stokoe) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →